| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22044 |
| Drug | Tisagenlecleucel |
| Brand | Kymriah® |
| Indication | For the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 28/06/2022 |
| Rapid review completed | 27/07/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/08/2022 |
| Pre-submission consultation with Applicant | 06/12/2022 |
| Full submission received from Applicant | 14/07/2023 |
| Preliminary review sent to Applicant | 06/02/2024 |
| NCPE assessment re-commenced | 08/03/2024 |
| Follow-up to preliminary review sent to Applicant | 11/04/2024 |
| NCPE assessment re-commenced | 18/04/2024 |
| Factual accuracy sent to Applicant | 27/05/2024 |
| NCPE assessment re-commenced | 05/06/2024 |
| Follow up to factual accuracy check sent to Applicant | 16/07/2024 |
| NCPE assessment re-commenced | 23/07/2024 |
| NCPE assessment completed | 12/08/2024 |
| NCPE assessment outcome | The NCPE recommends that tisagenlecleucel not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.